4528.T JPX
Ono Pharmaceutical Co., Ltd.
1W: -4.6%
1M: -6.5%
3M: -4.1%
YTD: -10.1%
1Y: +36.1%
3Y: -0.2%
5Y: +5.2%
¥2,278.50 ($14.43)
-11.50 (-0.50%)
Weekly Expected Move ±2.9%
¥2157
¥2224
¥2290
¥2356
¥2423
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$1.11T
+4.0% ▲
5Y CAGR: +8.2%
Total Liabilities
$249.9B
-9.4% ▼
5Y CAGR: +18.8%
Shareholders Equity
$850.7B
+8.7% ▲
5Y CAGR: +6.0%
Cash & Investments
$237.1B
+12.7% ▲
5Y CAGR: +17.7%
Total Debt
$120.9B
-17.6% ▼
5Y CAGR: +67.9%
Net Debt
-$116.1B
-100.6% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $69.1B | $96.1B | $166.1B | $204.6B | $237.0B |
| Short-Term Investments | $47.9B | $68.2B | $38.5B | $5.8B | $60M |
| Cash & ST Investments | $117.0B | $164.3B | $204.6B | $210.4B | $237.1B |
| Net Receivables | $99.8B | $114.4B | $136.1B | $135.0B | $145.9B |
| Inventory | $41.8B | $44.8B | $48.6B | $74.9B | $57.5B |
| Other Current Assets | $11.7B | $7.9B | $9.6B | $12.1B | $27.8B |
| Total Current Assets | $281.3B | $345.1B | $413.6B | $455.1B | $468.3B |
| Property, Plant & Equip. | $112.1B | $108.4B | $104.8B | $105.7B | $101.4B |
| Goodwill & Intangibles | $64.7B | $69.1B | $57.3B | $351.2B | $376.2B |
| Long-Term Investments | $252.5B | $252.7B | $297.2B | $96.5B | $101.3B |
| Other Non-Current Assets | $3.5B | $71.5B | $40.9B | $4.5B | $3.5B |
| Total Non-Current Assets | $457.9B | $537.3B | $500.1B | $608.9B | $638.2B |
| Total Assets | $739.2B | $882.4B | $913.7B | $1.06T | $1.11T |
| — Liabilities — | |||||
| Accounts Payable | $49.7B | $66.8B | $60.7B | $89.3B | $63.0B |
| Short-Term Debt | $2.3B | $2.5B | $2.3B | $30.0B | $35.4B |
| Deferred Revenue | $2.2B | $35.2B | $22.1B | $0 | $0 |
| Other Current Liabilities | -$1.5B | -$30.4B | -$19.4B | $8.8B | $31.4B |
| Total Current Liabilities | $65.9B | $122.9B | $103.6B | $148.3B | $163.6B |
| Long-Term Debt | $0 | $0 | $0 | $105.0B | $75.0B |
| Other Non-Current Liab. | $4.1B | $4.0B | $3.9B | $3.2B | $2.9B |
| Total Non-Current Liabilities | $11.6B | $11.7B | $11.4B | $127.5B | $86.2B |
| Total Liabilities | $77.5B | $134.6B | $115.1B | $275.8B | $249.9B |
| — Equity — | |||||
| Common Stock | $17.4B | $17.4B | $17.4B | $17.4B | $17.4B |
| Retained Earnings | $644.8B | $709.9B | $768.2B | $790.9B | $830.1B |
| Accumulated OCI | $51.2B | $51.7B | $53.2B | $19.8B | $48.7B |
| Total Stockholders Equity | $655.9B | $741.9B | $793.0B | $782.5B | $850.7B |
| Total Liabilities & Equity | $739.2B | $882.4B | $913.7B | $1.06T | $1.11T |
| — Key Metrics — | |||||
| Total Debt | $8.8B | $9.2B | $8.9B | $146.7B | $120.9B |
| Net Debt | -$60.3B | -$87.0B | -$157.3B | -$57.9B | -$116.1B |
| Total Investments | $300.3B | $320.9B | $335.6B | $102.3B | $101.4B |